← Research hub  ·  securities

APGE · Apogee Therapeutics $135.07 2026-SEP-02 16:00 EST

My allocationNot heldas of 2026-SEP-03 · allocation page ↗
Research: QT · SA · STK · FA1 mention
2026-AUG-09 · Jay Singh · Weekly SSR research call (premium) · Positiveinsight · source page ↗$134.65

In short: Arb-book housekeeping: "APGE announced it has received HSR approval, so no antitrust risk there" — the regulatory leg of the deal is clean.

Full passage: premium transcript (PDF).

SOD $134.65 (open 2026-AUG-07)

Nothing matches this filter.

Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.